James Woodruff Lillie Sells 22,082 Shares of Maplight Therapeutics (NASDAQ:MPLT) Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) insider James Woodruff Lillie sold 22,082 shares of Maplight Therapeutics stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $12.54, for a total value of $276,908.28. Following the completion of the sale, the insider directly owned 202,380 shares of the company’s stock, valued at approximately $2,537,845.20. This trade represents a 9.84% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

James Woodruff Lillie also recently made the following trade(s):

• On Thursday, May 7th, James Woodruff Lillie sold 721 shares of Maplight Therapeutics stock. The shares were sold at an average price of $28.28, for a total transaction of $20,389.88.
• On Wednesday, May 6th, James Woodruff Lillie sold 24,811 shares of Maplight Therapeutics stock. The stock was sold at an average price of $28.76, for a total transaction of $713,564.36.

Maplight Therapeutics Stock Down 0.2%

MPLT opened at $12.92 on Thursday. The company has a market capitalization of $550.65 million and a price-to-earnings ratio of -0.32. The firm has a 50-day moving average price of $29.68 and a 200-day moving average price of $24.80. Maplight Therapeutics, Inc. has a twelve month low of $9.10 and a twelve month high of $40.43.

Maplight Therapeutics (NASDAQ:MPLT) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($1.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.43). On average, sell-side analysts expect that Maplight Therapeutics, Inc. will post -5.22 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently commented on MPLT shares. Craig Hallum reaffirmed a “buy” rating and issued a $25.00 price target on shares of Maplight Therapeutics in a report on Tuesday, July 28th. Morgan Stanley reiterated an “equal weight” rating and set a $21.00 price objective (down from $34.00) on shares of Maplight Therapeutics in a research note on Tuesday, July 28th. Benchmark reissued a “buy” rating on shares of Maplight Therapeutics in a report on Monday, June 22nd. HC Wainwright cut their target price on Maplight Therapeutics from $45.00 to $26.00 and set a “buy” rating for the company in a research note on Tuesday, July 28th. Finally, Raymond James Financial assumed coverage on Maplight Therapeutics in a report on Wednesday, June 24th. They set a “strong-buy” rating and a $46.00 target price for the company. Four investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $34.42.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in MPLT. Strs Ohio bought a new position in shares of Maplight Therapeutics in the fourth quarter worth $53,000. Blue Owl Capital Holdings LP bought a new stake in Maplight Therapeutics during the fourth quarter valued at $5,745,000. Geode Capital Management LLC purchased a new position in Maplight Therapeutics during the fourth quarter worth about $6,835,000. Seven Grand Managers LLC purchased a new position in Maplight Therapeutics during the fourth quarter worth about $1,756,000. Finally, Goldman Sachs Group Inc. bought a new position in Maplight Therapeutics in the 4th quarter worth about $34,026,000.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.